StageZero Life Sciences Announces Warrant Extension
StageZero Life Sciences (TSX:SZLS / OTCQB:SZLSF) announced plans to extend the expiry date of 5,702,314 outstanding share purchase warrants to January 31, 2023. This decision responds to shareholder requests and aims to support past financing participants, potentially raising up to C$5.654 million if all warrants are exercised. The effective amendment date is set for February 18, 2022. StageZero focuses on early cancer detection and management through innovative diagnostics like Aristotle®, a multi-cancer blood test.
- Extension of 5,702,314 outstanding share purchase warrants to January 31, 2023.
- Potential capital raise of up to C$5.654 million if all warrants are exercised.
- Support for shareholders who participated in previous financing rounds.
- None.
TORONTO, ON / ACCESSWIRE / February 4, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that it has applied to the Toronto Stock Exchange (the "Exchange") to extend the expiry date of 5,702,314.00 outstanding common share purchase warrants (the "Warrants") to January 31, 2023. The Warrants consist of certain of the Company's Warrants that are currently due to expire in 2022.
The Warrants were originally issued pursuant to non-brokered private placements and debenture conversions. None of the Warrants to be extended are held, directly or indirectly, by any insiders of the Company.
The following table identifies the Warrants and their exercise price.
| Issue Date | Exercise Price | Current Expiry Date | Number of Warrants |
| 25-Mar-2019 | 0.72 | 25-Mar-2022 | 722,606.00 |
| 23-Apr-2019 | 0.8 | 23-Apr-2022 | 390,626.00 |
| 23-Apr-2019 | 0.96 | 23-Apr-2022 | 220,797.00 |
| 23-Apr-2019 | 1.528 | 22-Apr-2022 | 319,095.00 |
| 10-Jul-2019 | 1.48 | 10-Jul-2022 | 1,448,597.00 |
| 24-Jul-2019 | 1.48 | 24-Jul-2022 | 566,875.00 |
| 19-Feb-2020 | 0.56 | 19-Feb-2022 | 202,344.00 |
| 08-Jul-2020 | 0.56 | 18-Feb-2022 | 31,250.00 |
| 09-Jul-2020 | 0.56 | 18-Feb-2022 | 78,125.00 |
| 28-Sep-2020 | 0.56 | 18-Feb-2022 | 50,782.00 |
| 29-Sep-2020 | 0.56 | 18-Feb-2022 | 54,688.00 |
| 27-Oct-2020 | 0.56 | 18-Feb-2022 | 15,625.00 |
| 25-Jan-2021 | 0.56 | 18-Feb-2022 | 62,500.00 |
| 28-Jan-2021 | 0.56 | 18-Feb-2022 | 273,438.00 |
| 29-Jan-2021 | 0.56 | 18-Feb-2022 | 490,625.00 |
| 29-Jan-2021 | 0.56 | 18-Feb-2022 | 343,750.00 |
| 25-Feb-2021 | 0.56 | 18-Feb-2022 | 23,438.00 |
| 01-Mar-2021 | 0.56 | 18-Feb-2022 | 9,375.00 |
| 09-Mar-2021 | 0.56 | 18-Feb-2022 | 234,375.00 |
| 25-Mar-2021 | 0.56 | 18-Feb-2022 | 31,250.00 |
| 18-Aug-2021 | 0.56 | 18-Feb-2022 | 62,500.00 |
| 19-Aug-2021 | 0.56 | 18-Feb-2022 | 69,653.00 |
The effective date for amendments to the Warrants will be February 18, 2022, subject to the requisite approval of the Exchange.
"Responding to requests from the shareholders who have participated in previous financings, we have decided to extend the term of warrants granted during these financings, to show support for those who participate, and as a possible ongoing source of capital to fund our continuing growth - up to C
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences Ltd
View source version on accesswire.com:
https://www.accesswire.com/687263/StageZero-Life-Sciences-Announces-Warrant-Extension
FAQ
What is the new expiry date for StageZero Life Sciences warrants SZLSF?
How many warrants is StageZero Life Sciences extending?
What is the potential capital from the extended warrants for SZLSF?
When will the amendments to the warrants take effect for SZLSF?
